295 results about "Biocompatible polymers" patented technology

A three-dimensional scaffold for use in engineered tissue includes a repeated 3D geometry; and at least one of a hydrogel, a biocompatible polymer, and a bioprintable polymer. The repeated 3D geometry may include an open geometry including a plurality of interconnected nodes configured to be seeded with living cells. The scaffold may be formed via bioprinting. The three-dimensional scaffold may also be used for (1) 3D tissue modelling (for liver, kidney, gut, pancreas, heart, lung, spleen, etc.), (2) disease modeling of different tumor types such as breast, colorectal, lung, liver, brain, ovarian and others, (3) drug testing / therapeutic screening of small molecule drugs, peptides, proteins, antibodies, ADCs, gene therapies, RNA-based therapeutics, cell therapies, and tissue therapies, and (4) therapeutic / drug delivery (i.e., via delivery device that can be used to control drug release based on different patterns).

According to some embodiments, a patch for organ and / or tissue application is provided which comprises a biocompatible polymeric material having an auxetic architecture and further matching a stiffness ratio and / or Poisson's ratio of an organ or tissue to which the patch is applied. According to some further embodiments, biocompatible patches and methods of making the same are provided comprising providing a layer of hydrogel and forming an auxetic architecture by selectively crosslinking areas of the hydrogel via exposure to light, wherein the auxetic architecture is selected to match a stiffness ratio and Poisson's ratio of an organ to which the biocompatible patch is applied.

There is described an artificial intelligence wearable ECG skin patch (400) to detect sudden cardiac arrest. The wearable ECG monitoring patch (400) with AI based predictive analytics and remote based cardiac monitoring (615) system that can detect cardiac arrhythmias automatically in real-time and make a diagnosis with AI models trained with acquired data. The wearable skin has a biocompatible polymer patch (400) which captures the electrical signal through a flexible printed electronic technology based conducting ink and a substrate. The microcontroller controls (201), store and transmit the data packets. The IoT connected signal transmission is capable of recording and transferring the data packets through wireless communication. The AI engine is capable of analysing, evaluating, testing and providing the data packets of sudden cardiac arrest through a peak detector algorithm. The ECG skin patch (400) to detect and measure the sudden cardiac arrest with the R-R interval time series to obtain heart rate variability.

The present invention relates to nanoparticles comprising:-an association of at least one metal salt and at least one peptide; and-at least one biocompatible polymer.

The invention provides a sustained-release microneedle for treating ill-conditioned pregnancy and a preparation method and application thereof, and relates to the technical field of biological medicines.The sustained-release microneedle for treating ill-conditioned pregnancy comprises a base and a needle tip on the base, the needle tip part of the gel microneedle is made of heparin medicine, and the needle tip part of the gel microneedle is made of gelatin. The heparin medicine comprises heparin, heparin sodium, low-molecular heparin, low-molecular heparin sodium or low-molecular heparin calcium; the needle point part comprises a heparin photo-crosslinking monomer, and the base comprises a biocompatible polymer matrix. The sustained-release microneedle for treating pathological pregnancy provided by the embodiment of the invention has good mechanical strength, skin permeability and anticoagulant activity, can reduce skin bruises caused by subcutaneous injection of heparin, improves abortion caused by infection and inflammation and abortion caused by APS (anti-phospholipid antibody syndrome), can realize sustained release of drugs and increase of drug loading capacity, and has good application prospects. Sustainable drug delivery is achieved, and frequent injection is avoided.

The invention provides a continuous fiber bionic meniscus and a preparation method thereof, and relates to the technical field of medical materials. The continuous fiber bionic meniscus provided by the invention comprises a circumferential orientation layer and a radial orientation layer, the circumferential orientation layer is composed of continuous circumferential composite filaments; the radial orientation layer is composed of continuous radial composite filaments; the composite filament is formed by wrapping continuous fibers with a biocompatible polymer matrix. Continuous fibers are introduced into a polymer filament framework for reinforcement, collagen fibers are simulated through composite filaments, the biomechanical property of the meniscus implant can be improved, remarkable anisotropy is generated, meanwhile, the continuous fibers can maintain the mechanical strength in vivo for a long time, long-term maintenance of the functions of the implant is facilitated, and the service life of the implant is prolonged. Therefore, the functional requirements of the bionic meniscus implant are met. The bionic meniscus implant is prepared by using a continuous fiber 3D printing process, the production efficiency is high, the required equipment is less, and the method is suitable for personalized customization.

A construct includes a biocompatible polymer-based shape morphing hydrogel or cell condensate that is configured to undergo multiple, reversible, and / or controllable different shape transformations over time via either pre-programmed design or user-controlled environmental condition alterations, wherein the hydrogel is cytocompatible and, upon degradation, produces substantially non-toxic products.

The invention relates to the field of biological medicine, in particular to a water-soluble alginate microcarrier as well as a preparation method and application thereof. The alginate microcarrier comprises a carrier core structure and a shell surface modifier, the micro-carrier core layer is formed by carrying out plasma crosslinking on water-soluble alginate, ethylenediamine tetraacetic acid salt, nitrilotriacetic acid salt, diethylene triamine pentaacetic acid and water-soluble divalent metal salt, and light-sensitive alginate and a photoinitiator can also be added, so that the micro-carrier core layer has two crosslinking networks; the shell layer is composed of one of gelatin, collagen, fibrinogen, albumin and fibrin, or the gelatin, the collagen, the fibrinogen, the albumin and the fibrin and other biocompatible polymers; the obtained microcarrier has the characteristics of high transparency and rapid degradation, and adherent cells can be amplified in vitro; the microcarrier obtained in the invention can be used for mesenchymal stem cell culture, and can be rapidly degraded under a mild cell condition to harvest cells.

A waste collection system for collecting waste from a body of a patient. The waste collection system includes: an endoluminal stoma channel having a resilient deformable inner ring, an outer ring, a flexible polymer sleeve made from a biocompatible polymer and interconnecting the inner ring and the outer ring; an inner colostomy bag which can be detachably attached to the outer ring to collect and contain the waste; and a cover which can engage the outer ring in a sealed engagement, and where a portion of the flexible polymer sleeve and the inner ring are configured for insertion into a stoma formed in the body of the patient.

The application discloses a soluble microneedle composition for transdermal delivery of polypeptides and application thereof. The soluble microneedle composition comprises a first composition and a second composition; wherein the first composition comprises the following components in mass percentage: 20-60% polypeptides, 0.5-20% capryol 98, 10-40% first biocompatible polymer material and 0.5-20% first surfactant; the second composition comprises the following components in mass percentage: 98-99.75% second biocompatible polymer material and 0.25-2% second surfactant. The microneedle composition is used in the microneedle, and the problems of low transdermal efficiency and poor stability of polypeptides are solved.

The invention belongs to the technical field of hydrogel preparation, and relates to a cartilage-imitating multifunctional drug release hydrogel material and a preparation method thereof. According to the invention, biocompatible high polymer materials such as polyvinyl alcohol, chitosan, grape seed protein, acyl chloride, sulphobetaine methacrylate and lecithin are used as raw materials, a cartilage structure is simulated to prepare the multilayer hydrogel, gelatin and plant polyphenol are mixed as an adhesive to improve the binding capacity with subosseous bones, and a drug is loaded to improve the biological activity. The preparation method of the hydrogel material comprises the five steps of preparation of high-strength anti-swelling precursor hydrogel, introduction of double bonds through surface modification, introduction of a poly SBMA molecular brush through interfacial polymerization, drug loading and preparation of an adhesion layer. The hydrogel has excellent anti-swelling ability, lubricating property, anti-pollution ability, free radical scavenging ability, self-adhesion characteristic, drug controlled release ability and biocompatibility, and has important significance for widening the application of the hydrogel in the field of artificial cartilage.

The invention relates to the technical field of biomedical material modification, in particular to a sulfhydrylation biocompatible polymer derivative, a preparation method thereof, extracellular matrix imitating injectable in-situ cross-linked hydrogel and application thereof. According to the invention, a pre-acylation strategy is firstly carried out on the biocompatible polymer containing both amino and carboxyl, so that a three-dimensional cross-linked byproduct formed by coupling of self amido bonds is avoided, meanwhile, the number of side chain carboxyl for sulfhydrylation modification is increased, and the accurate and adjustable pre-acylation rate can optimize the physical and chemical properties of the derivative; meanwhile, a disulfide bond is used as a protective precursor, active sulfydryl is introduced through amido bond coupling, self-oxidation of the active sulfydryl in the reaction process is avoided, sulfydryl activity is guaranteed, hydrazine-containing reagents are avoided, safety is further improved, virus residues and immunological rejection risks are avoided, universality is high, and the application prospect is wide; and in combination with a high-concentration preparation method, the method has the advantage of large-scale production, and further widens the industrial application potential.

Disclosed herein are composite sheets and prosthetic medical devices formed therefrom. In an embodiment, a composite sheet has a thickness of 25-250 μm and comprises 10-70 mass %, based on the total mass of the composite sheet, of a knit fabric having thickness of 15-225 μm and comprising strands of 2-50 dtex, the strands comprising biocompatible polymer fibers, the strands comprising biocompatible polymer fibers, wherein the fabric comprises a thickness in a plurality of first locations, and pores in a plurality of second locations; and 30-90 mass %, based on the total mass of the composite sheet, of a polyurethane coating, wherein the polyurethane coating coats the fabric and fills the pores of the fabric such that the composite sheet is substantially impermeable to water.

Provided is a dry eye therapeutic agent that can selectively inhibit IFN-y, have no risk of biological contamination, and can be stored at room temperature. Provided is a dry eye therapeutic agent, comprising as an active ingredient a DNA oligonucleotide having a nucleotide sequence set forth in any of SEQ ID NO:1 to 3 and selectively binding to IFN-y. A base, X, in the sequence of the DNA oligonucleotide having the nucleotide sequence set forth in SEQ ID NO: 3 is an artificially produced base, and the artificially produced base may be chemically modified with a low-molecular-weight compound, a medium-molecular-weight compound, a large-molecular-weight compound, a biopolymer, or a biocompatible polymer.

The present application relates to fibers of one or more biocompatible polymers having a diameter of 1 nm to 10,000 nm, wherein the polymer has a main chain including a positively charged component from a zwitterionic portion. In addition, the present application discloses an implantable therapeutic delivery system and a method for forming the same, the implantable therapeutic delivery system comprising a shell defining a chamber, wherein the shell is porous and is formed by the fibers. The interior of the shell includes a cell preparation that releases a therapeutic agent from the chamber. The implantable therapeutic delivery system can be used to treat diabetes.

The invention relates to the technical field of biological medicine nano-drug delivery, in particular to a nano-drug delivery system based on a metal polyphenol network, and solves the problems that an existing MPN nano-drug delivery system is low in drug loading capacity, obvious in burst release, poor in stability, single in response and lack of targeting capacity. The system comprises a nanoparticle core formed by self-assembly of metal ions and polyphenol compounds, the surface of the nanoparticle core is coated with a biocompatible polymer shell, a hydrophobic drug is loaded inside the nanoparticle core, the particle size of the nanoparticle core is 50-300 nanometers, the nanoparticle core has pH responsiveness and a dynamic reversible coordination structure, and an organic solvent is not needed in the preparation process. The drug loading efficiency is remarkably improved, burst release is inhibited, the in-vivo stability is enhanced, tumor microenvironment responsive drug release is achieved, the circulation time is prolonged through the polymer shell, tumor accumulation is improved, and a safe and controllable delivery platform is provided for precise and efficient treatment.

Provided is a Hunner-type interstitial cystitis therapeutic agent that can selectively inhibit IFN-γ without risk of biological contamination and can be stored at room temperature. Provided is a Hunner-type interstitial cystitis therapeutic agent or a reagent for test and research, comprising as an active ingredient a DNA oligonucleotide having a nucleotide sequence set forth in any of SEQ ID NO:1 to 3 and selectively binding to IFN-γ. A base, X, in the sequence of the DNA oligonucleotide having the nucleotide sequence set forth in SEQ ID NO: 3 is an artificially produced base, and the artificially produced base may be chemically modified with a low-molecular-weight compound, a medium-molecular-weight compound, a high-molecular-weight compound, a biopolymer, or a biocompatible polymer.

Microparticulate compositions and methods for delivery and pulsatile release of one or more sting agonists and / or receptors have been developed. The compositions include polymeric microdevices formed from biodegradable and biocompatible polymers or co-polymers thereof including a shell and compartment(s) or discrete regions in the compartment(s) formed by an additive process such as micromolding, three dimensional printing and lithography. The compositions include microdevices that release individual doses of incorporated STING agonist and / or receptors at defined times, for example, in pulses up to several months after administration with essentially no leakage between releases.

A composition includes a drying method-applied fibrous acellular dermal matrix. Such a composition includes 48 to 95.5% by weight of a fibrous acellular dermal matrix; and 0.5 to 52% by weight of water. The composition has no biocompatible polymer added thereto. A method for preparing the composition includes steps of: (a) pulverizing an acellular dermal matrix to prepare a fibrous acellular dermal matrix; (b) adding water to the fibrous acellular dermal matrix to rehydrate it; and (c) heat-drying the rehydrated fibrous acellular dermal matrix.

The invention provides anisotropic thermoelectric hydrogel, which is characterized in that hydrogel is used as a matrix, and a thermoelectric material is dispersed and fixed in the hydrogel matrix; the hydrogel matrix is formed by biocompatible macromolecules through a directional freezing method or a mechanical stretching method, and has an anisotropic internal microstructure oriented in a single direction. Through a directional freezing or mechanical stretching process, a microstructure oriented in a single direction is constructed in the thermoelectric hydrogel, so that the hydrogel has anisotropy of shrinkage characteristics. The two preparation methods disclosed by the invention are both based on physical crosslinking and orientation technologies, complex chemical modification or expensive equipment is not needed, and effective design of the shrinkage anisotropy of the material is realized by controlling freezing conditions (such as liquid level height and cooling direction) or stretching parameters (such as stretching ratio and cycle index); and mutual conversion between heat energy and electric energy can be realized through a thermoelectric material in the hydrogel network.

The present invention relates to a scaffold for cartilage regeneration and a construction method therefor and, more specifically, to a scaffold for cartilage regeneration and a construction method therefor, wherein the scaffold is constructed by a scaffold construction device including a predetermined mold and structure, whereby the scaffold, even if produced in a large area, allows for excellent uniformity in the thickness of a biocompatible polymer sheet and in the pattern formed on the sheet, thus exhibiting excellent cartilage regeneration effects and adhesion to the affected area.

The present invention relates to a composition comprising a fibrotic acellular dermal matrix, which does not apply a biocompatible polymer, thereby having improved physical properties and tensile strength, and which is easier to use than in the prior art, and a method for preparing the same.

The invention provides powder with reversible photochromic performance as well as a preparation method and application thereof, and the powder with reversible photochromic performance is a photochromic microcapsule and consists of a core material and a wall material, the core material accounts for 30%-50% of the total weight of the microcapsule, and the wall material accounts for 50%-70% of the total weight of the microcapsule; the core material is an indoline spiroheterocyclic compound, and the wall material is a biocompatible polymer. The core material is an indoline spiroheterocyclic compound, and the wall material is a biocompatible polymer; the powder is prepared by taking indoline spiropyran as a photochromic core material through a microcapsule coating process, has reversible response characteristics of developing under ultraviolet irradiation and decolorizing under strong light irradiation, and can be compounded with a tattooing pigment matrix to obtain a tattooing product with active developing and decolorizing regulation and control functions. The problem that the photochromic tattoo pigment is irreversible in color change is solved, and meanwhile the photochromic tattoo pigment has good stability and biocompatibility.

The invention provides responsive release polypeptide hydrogel. The hydrogel comprises a gel product of a raw material composition containing the following raw material components: (A) a biocompatible polymer containing at least two sulfydryl groups; (B) a matrix metalloproteinase substrate polypeptide; (C) a compound containing a phenolic hydroxyl group structure; (D) a cross-linking agent; and (E) water; the sequence of the matrix metalloproteinase substrate polypeptide is at least one of the following sequences (b1) to (b2): (b1) Cys-Pro-Leu-Gly-Val-Arg-Gly-Arg-Gly-Asp-Ser, (b2) Cys-Pro-Leu-Gly-Val-Arg-Gly-Asp-Ser, (b3) Cys-Pro-Leu-Gly-Val-Arg-Gly (b2), Dnp-Pro-Leu-Gly-Met-Trp-Ser-Arg-C-ys, and (b3), Dnp-Pro-Leu-Gly- The responsive release polypeptide hydrogel can release polypeptide in a cell microenvironment to promote tissue regeneration and repair, and can be used for preparing muscle-bone healing promoting materials and treating ligament injury diseases such as rotator cuff injury.

The invention relates to an acellular matrix material with biological functional activity and a preparation method thereof. The preparation method comprises the following steps: 1) providing an acellular matrix material subjected to crosslinking treatment; 2) reacting the crosslinked acellular matrix material with a biocompatible polymer, wherein the biocompatible polymer has a reactive group and a first subject and / or guest molecule; the reactive group is covalently bonded to a functional group on the acellular matrix material; and 3) reacting the acellular matrix material obtained in the step 2) with a second subject and / or guest molecule modified by a biological functional active substance through subject-guest interaction. Through the mode, the anti-calcification performance and the biological activity of the acellular matrix material can be improved at the same time, and the acellular matrix material is flexibly endowed with various biological function activities.

Provision of drug-containing nanofibers. [Solution] A drug-containing nanofiber containing a biodegradable polymer or biocompatible polymer and a drug.

The present invention relates to a cosmetic composition for improving skin elasticity or reducing pore size, comprising an amphiphilic biocompatible polymer. The composition promotes collagen production, inhibits collagen degradation, and suppresses elastin degradation, and thus can be effectively used as a cosmetic composition for reducing the number of pores and decreasing pore areas.

To allow superior control of electrodeposition on indented portions of an electrodeposition target.SOLUTION: A method of making a valve structure includes a step of rotating a mandrel and an electrodeposition target attached to the mandrel about a rotational axis of the mandrel. The target includes an exterior surface having at least one conductive surface portion and at least one non-conductive surface portion. The method also includes a step of electrodepositing a polymer matrix of a biodegradable, biocompatible polymer composition onto the at least one conductive surface portion and the at least one non-conductive surface portion of the exterior surface of the rotating electrodeposition target to form the valve structure.SELECTED DRAWING: Figure 1A

In various embodiments tolerogenic nanoparticles are provided that induce immune tolerance to one or more desired antigen(s) and / or that reduce an immune response to those antigen(s). In certain embodiments the tolerogenic nanoparticle comprises a nanoparticle comprising a biocompatible polymer; an antigen disposed within or attached to said biocompatible polymer where said antigen comprises an antigen to which immune tolerance is to be induced by administration of said tolerogenic nanoparticle to a mammal; and a first targeting moiety that binds to a scavenger receptor in the liver, and / or a second targeting moiety that binds to a mannose receptor in the liver, and / or a third targeting moiety that binds to hepatocytes, wherein said first and / or second and / or third targeting moiety are attached to the surface of said nanoparticle.

The invention provides a medical beauty-grade sensitive skin repair dressing with a gamma-polyglutamic acid controlled release function, and belongs to the technical field of biomedical materials. The repair dressing is composed of controlled release microspheres dispersed in a matrix material, the controlled release microspheres take modified gamma-polyglutamic acid as an active core material and a biocompatible high polymer material as a wall material, and the matrix material comprises a medical grade gel matrix, a moisturizing component and an anti-inflammatory soothing component. The gamma-polyglutamic acid is subjected to acylation or graft modification to improve the stability and biocompatibility of the gamma-polyglutamic acid, and 12-72h gradient release of the gamma-polyglutamic acid is realized by virtue of the controlled release microspheres prepared by virtue of an emulsification-crosslinking method or a solvent evaporation method; meanwhile, through the synergistic matching of the matrix components, the dressing is endowed with the moisturizing, anti-inflammatory and soothing effects. The dressing can effectively reduce wound inflammatory response after medical art, promote epidermal cell proliferation and improve the water content and barrier function of a sensitive skin cuticle, and is suitable for scenes of wound repair after medical art, sensitive skin barrier reconstruction and the like.